This week
Suggest a nameObligation Marketing for AI Builders
The 7-Rung LadderThe 8-Type TaxonomyWrapper or WinnerThe Sample ColumnThe Signal
Updated through the day. Every headline links straight to the source. The two lines underneath are ours.
This is serious work on adaptive experimental design at scale. The biology-in-the-loop framing is honest: you use learned priors to pick the next experiment, then integrate real results. For biotech founders using ML to accelerate discovery, this is a working blueprint. The transfer from historical data matters more than any single technique.
This is the research-grade version of item 2, with more technical depth. Nine billion variant predictions that used to require wet lab validation. The immediate application is rare disease research, but the longer play is real-time genomic drug design. For researchers: your baseline just shifted. For biotech founders: your moat got thinner.
This is a real capability shift in computational biology. The tool maps what would take years of lab work, enabling researchers to predict effects of genetic variants at scale. For builders in biotech: this is now table stakes. For investors: biological ML is moving from research papers to applied pipelines.